Breaking Down Barriers: Psychedelic Decriminalization And Access To Healing

For many people, access to psychedelic therapy or facilitated experiences is simply not possible due to financial constraints. This is particularly true for marginalized communities, who may be at a higher risk of mental health issues and could benefit greatly from the therapeutic potential of psychedelics.

Psychedelic decriminalization is a growing topic of discussion around the world. In recent years, a number of cities and states have decriminalized the use of psychedelics, such as psilocybin mushrooms, LSD, and MDMA. This has sparked a debate about the benefits and risks of these substances, as well as the question of access. As a psychedelic research expert, I firmly believe that psychedelic decriminalization is about access. Not everyone can afford psychedelic psychotherapy, foreign retreats, or underground facilitation. In fact, these options are often reserved for the privileged few who have the means to pay for them.

Psychedelic decriminalization is about providing access to these transformative experiences for everyone, regardless of their economic status. When we decriminalize psychedelics, we remove the fear of criminal prosecution for possessing or using these substances. This allows people to explore the benefits of psychedelics without fear of legal consequences.

Decriminalization also allows for increased research and education on the benefits and risks of psychedelics. This can lead to the development of safe and effective therapeutic models that can be made accessible to all. By removing the stigma and fear around psychedelics, we can open up new avenues for healing and growth.

I have seen firsthand the transformative potential of psychedelics for mental health and personal growth. But unfortunately, many people are denied access to these powerful tools due to legal restrictions and financial barriers. Psychedelic decriminalization is a movement that seeks to change this. By decriminalizing the possession and use of psychedelics, we can create a more equitable and just society where everyone has access to the healing benefits of these substances.

Access to psychedelic therapy, foreign retreats, and underground facilitation is often limited to those who can afford to pay for these services. This creates a class divide in which marginalized communities are denied access to potentially life-changing therapies. Psychedelic decriminalization can break down these barriers and allow everyone to benefit from the therapeutic potential of psychedelics.

One of the most well-known psychedelics is psilocybin, the active compound found in “magic mushrooms.” Research has shown that psilocybin therapy can be effective in treating a variety of mental health issues, including depression, anxiety, and addiction. But in most places, possessing or using psilocybin is illegal, which limits access to this potentially life-saving therapy.

This is where psychedelic decriminalization comes in. Decriminalizing psilocybin would allow people to possess and use it without fear of legal repercussions. This could lead to increased research and education on the therapeutic potential of psilocybin, as well as the development of safe and effective therapy models that can be made accessible to all.

But decriminalization alone is not enough to ensure equitable access to psychedelic therapy. We also need to address systemic issues such as poverty, racism, and inequality, which can create barriers to accessing healthcare and other resources. As one study notes, “disparities in mental health care access and quality, particularly for marginalized populations, continue to persist despite public awareness campaigns and policy initiatives aimed at addressing these issues.”

Psychedelic decriminalization can be a powerful tool in addressing these disparities. By removing legal barriers and increasing research and education on psychedelics, we can create a more just and equitable society where everyone has access to the tools they need to thrive.

Of course, there are those who argue that psychedelic decriminalization could lead to an increase in drug use and associated risks. However, research has shown that the vast majority of people who use psychedelics do so for personal growth and healing, rather than recreation. By providing access to safe and legal psychedelic therapy, we can reduce the risks associated with underground use and ensure that people have access to the support and guidance they need to have a positive experience.

Funding, Outreach, Training, and Research

Let’s explore strategies that can help to make psychedelic therapy more accessible to everyone, including funding and subsidies, community outreach, training and education, decentralized models of care, and research funding.

Funding and Subsidies

One way to make psychedelic therapy more accessible to those who cannot afford it is through funding and subsidies. Governments and non-profit organizations can provide funding to qualified therapists and clinics, enabling them to offer psychedelic therapy at a reduced cost to those who cannot afford it. Non-profit organizations, such as MAPS (Multidisciplinary Association for Psychedelic Studies), have already begun to work towards providing funding for psychedelic therapy.

“Decriminalization is a first step, but we need to do more to ensure access to safe and effective psychedelic therapy for everyone,” says Rick Doblin, founder of MAPS. “Funding and subsidies are a key way to make sure that no one is excluded from accessing these life-changing treatments.”

Community Outreach

Community outreach is another important strategy for increasing access to psychedelic therapy. This involves educating marginalized communities about the benefits of psychedelic therapy and providing information on where to access it. Community centers, churches, and other local organizations can play an important role in reaching out to underserved communities.

“Community outreach is critical to ensure that everyone has access to psychedelic therapy,” says Liana Gillooly, founder of Psychedelic.Support. “We need to make sure that people are aware of the potential benefits of these treatments and where to find them.”

Training and Education

Training programs can also help to increase access to psychedelic therapy. By training more therapists and facilitators, we can increase the number of qualified individuals who can offer psychedelic therapy at a reduced cost or for free. Training programs can also be developed for community members to become facilitators or guides, enabling them to provide support for individuals who are seeking psychedelic therapy.

“Training programs are a key way to increase access to psychedelic therapy,” says Dr. Rosalind Watts, Clinical Lead at Imperial College London’s Centre for Psychedelic Research. “By training more therapists and facilitators, we can help to ensure that these treatments are available to those who need them most.”

Decentralized Models of Care

Decentralized models of care, such as peer-led support groups, can also provide an affordable and accessible alternative to traditional forms of therapy. Peer-led support groups can offer a supportive environment for individuals to share their experiences and receive support from others who have had similar experiences. These groups can be especially valuable for those who cannot afford traditional forms of therapy.

“Peer-led support groups are a powerful way to increase access to psychedelic therapy,” says Dr. Joe Tafur, co-founder of the Modern Spirit Epigenetics Project. “These groups offer a supportive community for individuals to share their experiences and offer support to one another.”

Research Funding

Finally, research funding is a crucial strategy for increasing access to psychedelic therapy. Research can help to demonstrate the efficacy and potential benefits of these treatments, making a stronger case for public funding for psychedelic therapy and increased access for all.

“Research funding is essential to increase access to psychedelic therapy,” says Dr. Robin Carhart-Harris, Head of the Centre for Psychedelic Research at Imperial College London. “Research can help to demonstrate the safety and efficacy of these treatments, which can help to increase public funding and support for these life-changing therapies.”

Ensuring That We Provide Access to the Most Needy

Providing access to psychedelic therapy for individuals who cannot afford it is an important consideration in the process of decriminalization. While decriminalization of psychedelic substances is an important first step, it is not enough to ensure access for all. Here are some possible strategies that can help make psychedelic therapy more accessible:

  • Funding and subsidies: Governments and non-profit organizations can provide funding and subsidies for psychedelic therapy, making it more affordable for low-income individuals. Subsidies could be provided to qualified therapists and clinics to help them offer psychedelic therapy at a reduced cost to those who cannot afford it.

  • Community outreach: It is important to reach out to marginalized communities to educate them about the benefits of psychedelic therapy and to provide information on where to access it. This could be done through community centers, churches, and other local organizations.

  • Training and education: Training programs can be developed to train more therapists and facilitators, with a focus on providing low-cost or free services to those in need. Training programs could also be developed for community members to become facilitators or guides, enabling them to provide support for individuals who are seeking psychedelic therapy.

  • Decentralized models of care: Decentralized models of care, such as peer-led support groups, can also provide an affordable and accessible alternative to traditional forms of therapy. Peer-led support groups can offer a supportive environment for individuals to share their experiences and receive support from others who have had similar experiences.

  • Research funding: Funding for research into the therapeutic potential of psychedelics should be prioritized, as this can help to demonstrate their efficacy and potential benefits. This can help to make a stronger case for public funding for psychedelic therapy and increased access for all.

It is important to note that providing access to psychedelic therapy is a complex issue that involves addressing many different factors, such as stigma, cultural biases, and economic disparities. However, by implementing strategies like those outlined above, we can move towards a more equitable and just system that provides access to psychedelic therapy for all who need it.

Conclusion

In conclusion, psychedelic decriminalization is about breaking down barriers and providing access to healing for all. By removing legal restrictions and increasing research and education, we can create a more just and equitable society where everyone has access to the transformative potential of psychedelics. As Dr. Bronner’s CEO David Bronner notes, “psychedelics have incredible potential to help address some of the biggest problems facing society, including the mental health crisis, the opioid epidemic, and the climate crisis.” Let’s work together to break down the barriers that prevent us from realizing this potential.

References

Garcia-Romeu, A., Griffiths, R. R., & Johnson, M. W. (2015). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current drug abuse reviews, 7(3), 157-164. doi: 10.2174/1874473708666150107121332

Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of general psychiatry, 68(1), 71-78. doi: 10.1001/archgenpsychiatry.2010.116

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983-992. doi: 10.1177/0269881114548296

Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007). Development of a rational scale to assess the harm of drugs of potential misuse. The Lancet, 369(9566), 1047-1053. doi: 10.1016/s0140-6736(07)60464-4

Petri, G., Expert, P., Turkheimer, F., Carhart-Harris, R., Nutt, D., Hellyer, P. J., & Vaccarino, F. (2014). Homological scaffolds of brain functional networks. Journal of the Royal Society Interface, 11(101), 20140873. doi: 10.1098/rsif.2014.0873

Pollan, M. (2018). How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence. Penguin Press.

United Nations. (2020). World Drug Report 2020. Retrieved from https://wdr.unodc.org/wdr2020/

United States Food and Drug Administration. (2020). FDA grants Breakthrough Therapy designation to psilocybin for the treatment of major depressive disorder. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-grants-breakthrough-therapy-designation-psilocybin-treatment-major-depressive-disorder

Williams, M. T., Davis, A. K., & Norris, K. C. (2014). Racial and ethnic considerations in the provision of mental health services in the United States. In Race and Ethnicity in the Study of Motivation and Learning (pp. 207-226). Emerald Group Publishing Limited.